Amgen Inc. (NASDAQ:AMGN)’s share price hit a new 52-week high during trading on Monday . The company traded as high as $185.20 and last traded at $185.24, with a volume of 1,612,394 shares trading hands. The stock had previously closed at $180.64.
Several equities analysts have recently issued reports on AMGN shares. UBS AG reiterated a “neutral” rating and set a $174.00 price objective (down from $175.00) on shares of Amgen in a research report on Monday, May 22nd. Oppenheimer Holdings, Inc. reiterated a “buy” rating and set a $203.00 price objective on shares of Amgen in a research report on Thursday. Jefferies Group LLC reiterated a “buy” rating and set a $195.00 price objective on shares of Amgen in a research report on Tuesday, July 11th. Leerink Swann reiterated a “market perform” rating and set a $161.00 price objective on shares of Amgen in a research report on Thursday, June 22nd. Finally, BMO Capital Markets reissued a “buy” rating and set a $198.00 target price (down previously from $200.00) on shares of Amgen in a report on Monday, May 22nd. One analyst has rated the stock with a sell rating, eleven have given a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $186.04.
The company has a 50 day moving average of $173.58 and a 200 day moving average of $168.73. The company has a market capitalization of $135.38 billion, a price-to-earnings ratio of 16.899 and a beta of 1.35.
Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. The firm had revenue of $5.81 billion during the quarter, compared to analyst estimates of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The company’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter last year, the business earned $2.84 earnings per share. On average, analysts forecast that Amgen Inc. will post $12.57 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Thursday, August 17th were given a $1.15 dividend. The ex-dividend date was Tuesday, August 15th. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.55%. Amgen’s dividend payout ratio (DPR) is currently 41.93%.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Carderock Capital Management Inc. grew its holdings in shares of Amgen by 3.2% in the first quarter. Carderock Capital Management Inc. now owns 27,629 shares of the medical research company’s stock worth $4,533,000 after purchasing an additional 848 shares during the last quarter. Howe & Rusling Inc. boosted its holdings in Amgen by 1.1% in the first quarter. Howe & Rusling Inc. now owns 2,956 shares of the medical research company’s stock valued at $485,000 after acquiring an additional 31 shares in the last quarter. First United Bank Trust boosted its holdings in Amgen by 3.1% in the first quarter. First United Bank Trust now owns 6,254 shares of the medical research company’s stock valued at $1,026,000 after acquiring an additional 187 shares in the last quarter. Howland Capital Management LLC boosted its holdings in Amgen by 42.8% in the first quarter. Howland Capital Management LLC now owns 2,182 shares of the medical research company’s stock valued at $358,000 after acquiring an additional 654 shares in the last quarter. Finally, Reliance Trust Co. of Delaware boosted its holdings in Amgen by 9.4% in the first quarter. Reliance Trust Co. of Delaware now owns 10,578 shares of the medical research company’s stock valued at $1,735,000 after acquiring an additional 910 shares in the last quarter. 78.14% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “Amgen Inc. (AMGN) Hits New 52-Week High at $185.20” was originally reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://sportsperspectives.com/2017/09/11/amgen-inc-amgn-hits-new-52-week-high-at-185-20.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.